nach oben

Digestive Diseases and Sciences

Erschienen in:

01.06.2013 | Original Article

Positive Expression of LSD1 and Negative Expression of E-cadherin Correlate with Metastasis and Poor Prognosis of Colon Cancer

verfasst von: Ding Jie, Zhang Zhongmin, Liao Guoqing, Liu Sheng, Zhang Yi, Wen Jing, Zeng Liang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The first identified lysine-specific demethylase, LSD1, plays an important role in the metastatic progression of several types of cancer.

Aims

The aim of this study was to investigate LSD1, E-cadherin, and N-cadherin expression in colon cancer specimens and their clinical significance.

Methods

The expression of LSD1, E-cadherin, and N-cadherin in colon cancer specimens was determined by immunohistochemistry, and the relationship between the expression of the respective molecules and clinicopathological characteristics was analyzed.

Results

The positive expression rates of LSD1, E-cadherin, and N-cadherin in colon cancer specimens were 66.7 % (72/108), 85.2 % (92/108), and 41.7 % (45/108), respectively. LSD1 was significantly more highly expressed in colon cancer specimens classified as high TNM stage lesions and with distant metastasis (P < 0.05). Further analysis demonstrated that LSD1 expression was positively correlated with lymph node and distant metastases (P < 0.05). However, E-cadherin expression was significantly downregulated in colon cancer specimens classified as high TNM stage lesions and with distant metastasis (P < 0.05), whereas the expression of N-cadherin did not differ significantly according to clinical and pathological characteristics (P > 0.05). Correlation analysis revealed that LSD1 expression was negatively correlated with E-cadherin expression (r _s = −0.318, P = 0.001), but not evidently correlated with N-cadherin expression (r _s = 0.182, P = 0.06). Colon cancer specimens with positive LSD1 expression and negative E-cadherin expression were correlated with significantly lower overall survival.

Conclusions

LSD1 showed a significantly higher expression, in contrast to the significantly lower expression of E-cadherin, in colon cancer specimens classified as high TNM stage lesions and with distant metastasis. Positive expression of LSD1 and negative expression of E-cadherin may be predictors of a worse colon cancer prognosis.

Cui R, Okada Y, Jang SG, et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut. 2011;60:799–805.PubMedCrossRef

Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688–1694.PubMedCrossRef

Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–378.PubMedCrossRef

Boyer B, Vallés AM, Edme N. Induction and regulation of epithelial–mesenchymal transitions. Biochem Pharmacol. 2000;60:1091–1099.PubMedCrossRef

Kang Y, Massagué J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–279.PubMedCrossRef

Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613–1618.PubMed

Chang ZG, Wei JM, Qin CF, et al. Suppression of the epidermal growth factor receptor inhibits epithelial–mesenchymal transition in human pancreatic cancer PANC-1 cells. Dig Dis Sci. 2012;57:1181–1189.PubMedCrossRef

Dai YH, Tang YP, Zhu HY, et al. ZEB2 promotes the metastasis of gastric cancer and modulates epithelial mesenchymal transition of gastric cancer cells. Dig Dis Sci. 2012;57:1253–1260.PubMedCrossRef

Batlle E, Sancho E, Francí C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84–89.PubMedCrossRef

10.

Lin T, Ponn A, Hu X, et al. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene. 2010;29:4896–4904.PubMedCrossRef

11.

Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem. 2010;79:155–179.PubMedCrossRef

12.

Cho HS, Suzuki T, Dohmae N, et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011;71:655–660.PubMedCrossRef

13.

Lv T, Yuan D, Miao X, et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE. 2012;7:e35065.PubMedCrossRef

14.

Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295–308.PubMedCrossRef

15.

Serce N, Gnatzy A, Steiner S, et al. Elevated expression of LSD1 (lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol. 2012;12:13.PubMedCrossRef

16.

Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumors by p53 and MDM2 immuno-histochemistry. J Pathol. 2005;207:251–259.PubMedCrossRef

17.

Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol Clin North Am. 1992;19:227–246.PubMed

18.

Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159.PubMedCrossRef

19.

Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21–33.PubMedCrossRef

20.

Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–953.PubMedCrossRef

21.

Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell. 2007;25:1–14.PubMedCrossRef

22.

Mimasu S, Sengoku T, Fukuzawa S, et al. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem Biophys Res Commun. 2008;366:15–22.PubMedCrossRef

23.

Yang M, Culhane JC, Szewczuk LM, et al. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol. 2007;14:535–539.PubMedCrossRef

24.

Lee MG, Wynder C, Cooch N, et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437:432–435.PubMed

25.

Gatta R, Mantovani R. NF-Y substitutes H2A–H2B on active cell-cycle promoters: recruitment of CoREST-KDM1 and fine-tuning of H3 methylations. Nucleic Acids Res. 2008;36:6592–6607.PubMedCrossRef

26.

Wang Y, Zhang H, Chen Y, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138:660–672.PubMedCrossRef

27.

Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010;31:512–520.PubMedCrossRef

28.

Zhao ZK, Dong P, Gu J, et al. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumour Biol. 2012. doi:10.1007/s13277-012-0525-x.

29.

Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog. 2011;50:931–944.PubMedCrossRef

30.

Hayami S, Kelly JD, Cho HS, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128:574–586.PubMedCrossRef

31.

Bennani-Baiti IM, Machado I, Llombart-Bosch A, et al. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43:1300–1307.PubMedCrossRef

32.

Huang J, Sengupta R, Espejo AB, et al. p53 is regulated by the lysine demethylase LSD1. Nature. 2007;449:105–108.PubMedCrossRef

33.

Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 2007;282:15471–15475.PubMedCrossRef

34.

Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009;69:2065–2071.PubMedCrossRef

35.

Ferrari-Amorotti G, Fragliasso V, Esteki R, et al. Inhibiting interactions of lysine demethylase LSD1 with Snail/Slug blocks cancer cell invasion. Cancer Res. 2012;. doi:10.1158/0008-5472.CAN-12-1739.PubMed

36.

Wu ZQ, Li XY, Hu CY, et al. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci USA. 2012;109:16654–16659.PubMedCrossRef

37.

Chen Y, Jie W, Yan W, et al. Lysine-specific histone demethylase 1 (LSD1): a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr. 2012;22:53–59.PubMedCrossRef

38.

Huang Y, Greene E, Murray Stewart T, et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA. 2007;104:8023–8028.PubMedCrossRef

39.

Angst BD, Marcozzi C, Magee AI. The cadherin superfamily. J Cell Sci. 2001;114:625–626.PubMed

40.

Greenspon J, Li R, Xiao L, et al. Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function. Dig Dis Sci. 2011;56:1342–1353.PubMedCrossRef

41.

Hazan RB, Qiao R, Keren R, et al. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155–163.PubMedCrossRef

42.

Castro Alves C, Rosivatz E, Schott C, et al. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol. 2007;211:507–515.PubMedCrossRef

43.

Dorudi S, Hanby AM, Poulsom R, et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995;71:614–616.PubMedCrossRef

44.

Gravdal K, Halvorsen OJ, Haukaas SA, et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13:7003–7011.PubMedCrossRef

45.

Hulit J, Suyama K, Chung S, et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 2007;67:3106–3116.PubMedCrossRef

46.

Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009;21:665–674.PubMedCrossRef

47.

Hazan R, Phillips G, Qiao R, et al. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779–790.PubMedCrossRef

48.

Christofori G. Snail1 links transcriptional control with epigenetic regulation. EMBO J. 2010;29:1787–1789.PubMedCrossRef

49.

Lin Y, Wu Y, Li J, et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 2010;29:1803–1816.PubMedCrossRef

Titel: Positive Expression of LSD1 and Negative Expression of E-cadherin Correlate with Metastasis and Poor Prognosis of Colon Cancer
verfasst von: Ding Jie
Zhang Zhongmin
Liao Guoqing
Liu Sheng
Zhang Yi
Wen Jing
Zeng Liang
Publikationsdatum: 01.06.2013
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 6/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2552-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Positive Expression of LSD1 and Negative Expression of E-cadherin Correlate with Metastasis and Poor Prognosis of Colon Cancer

Abstract

Background

Aims

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Disrupted Circadian Rhythmicity of the Intestinal Glucose Transporter SGLT1 in Zucker Diabetic Fatty Rats

Probiotics Can Alleviate Cardiopulmonary Bypass-Induced Intestinal Mucosa Damage in Rats

Claudin-2 Regulates Colorectal Inflammation via Myosin Light Chain Kinase-Dependent Signaling

Endoscopic Management of Esophageal Cancer After Definitive Chemoradiotherapy

Endoscopic Papillary Large Balloon Dilatation Alone Is Safe and Effective for the Treatment of Difficult Choledocholithiasis in Cases of Billroth II Gastrectomy: A Single Center Experience

Changes of the Intestinal Microbiota, Short Chain Fatty Acids, and Fecal pH in Patients with Colorectal Cancer

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin